Evaluation of the protective efficacy of four newly identified surface proteins of Erysipelothrix rhusiopathiae. Issue 52 (18th December 2018)

• Record Type: Journal Article
• Authors: Zhu, Weifeng; Wu, Chao; Kang, Chao; Cai, Chengzhi; Wang, Ya; Li, Jingtao; Zhang, Qiang; Sun, Xiaomei; Jin, Meilin
• Is Part Of: Vaccine. Volume 36:Issue 52(2018)
• Page Start: 8079
• Page End: 8083
• Publication Date: 2018-12-18
• Subjects: CbpB -- Bactericidal -- HP0728 -- HP1472 -- Protective antigen -- GAPDH; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.10.071
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Erysipelothrix rhusiopathiae is the causative agent of animal erysipelas and human erysipeloid. Bacterial surface proteins are promising vaccine candidates. We recently identified 3 E. rhusiopathiae surface proteins (GAPDH, HP0728, and HP1472) and characterized their roles as virulence factors. However, their efficacy as protective antigens is still unknown. The N-terminal region of a previously identified surface protein, CbpB (CbpB-N), is speculated to be a protective antigen, but this needs to be verified. The aim of this study was to evaluate the protective efficacy of GAPDH, HP0728, HP1472, and CbpB-N. Immunization with recombinant GAPDH provided complete protection in a mouse model, recombinant CbpB-N provided partial protection, while recombinant HP0728 and HP1472 provided no protection. Recombinant GAPDH also provided good protection in a pig model. GAPDH antiserum exhibited significant blood bactericidal activity against E. rhusiopathiae. In conclusion, GAPDH and CbpB-N were found to be protective antigens of E. rhusiopathiae, and GAPDH is a promising vaccine candidate.